JGC
MDGL icon

J. Goldman & Co’s Madrigal Pharmaceuticals MDGL Stock Holding History

J. Goldman & Co’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.05M Buy
+2,000
New +$956K 0.03% 411
2023
Q3 		– Sell
-13,500
Closed -$3.12M – 435
2023
Q2 		$3.12M Buy
+13,500
New +$3.66M 0.11% 175
2022
Q4 		– Sell
-27,000
Closed -$1.75M – 440
2022
Q3 		$1.75M Buy
+27,000
New +$1.88M 0.08% 220

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

J. Goldman & Co's MDGL Position: Q4 2025 in Review

J. Goldman & Co sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2025, closing a stake of 1,449 shares — an estimated $665K sold.

J. Goldman & Co first reported a position in MDGL in Q2 2013 and held it in 6 quarters. The position peaked at $3.27M in Q1 2025. 387 funds tracked by Wall St. Rank hold MDGL as of Q4 2025.

  • J. Goldman & Co reported no remaining Madrigal Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • J. Goldman & Co sold 1,449 Madrigal Pharmaceuticals shares in Q4 2025, an estimated $665K.
  • J. Goldman & Co first reported a position in Madrigal Pharmaceuticals in Q2 2013 and held it in 6 quarters.
  • J. Goldman & Co's Madrigal Pharmaceuticals position peaked at $3.27M in Q1 2025.
  • 387 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2025.

Based on J. Goldman & Co's 13F filing for Q4 2025, filed 17 Feb 2026.